MedPath

Effects of rebamipide on healing of low-dose aspirin-induced small intestinal mucosal injury- A pilot study

Not Applicable
Conditions
small intestinal injury
Registration Number
JPRN-UMIN000003463
Lead Sponsor
Osaka City University Graduate School of Medicine Osaka Medical College Kyoto Prefectural University of Medicine Saga University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
45
Inclusion Criteria

Not provided

Exclusion Criteria

1) Subjects with the diseases which induce small intestinal injury such as Chrohn's disease, gastrointestinal stromal tumor, small intestinal tumor. 2) The subject taking drugs which have potential to induce small intestinal injury such as NSAIDs, anticancer drugs. 3) The subject taking antibiotics, sulfasalazine, prostaglandin analog, corticosteroids, free radical depressant, elastase depressant, mucoprotective drugs and drugs which have potential to improve small intestinal injury. 4) The subject having evident small intestinal bleeding. 5) The subjects having diverticula and diaphragm-like stenosis in the small intestine. 6) The subject who have renal and hepatic disfunction. 7) The subjects who has allergic hypersensitivity against rebamipide. 8) The subject who participate in other clinical studies within 4 weeks. 9) The subjects who are judged to be inappropriate for this study by doctors conducting the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Capsule endoscopic findings (number of ulcers/erosions)
Secondary Outcome Measures
NameTimeMethod
ewis Score Symptom assessment (anemia, melena, complications) Safety
© Copyright 2025. All Rights Reserved by MedPath